Jesús Iñigo Martínez

Jesús Iñigo Martínez

Auto-generated profile, based on publicly available information

Jesús Iñigo Martínez

Directorate General of Public Health, Regional Ministry of Health of Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Eurosurveillance
Verified
Journal Article
Open access
LMLaura Montero Morales
Laura Montero Morales
JBJosé Francisco Barbas del Buey
José Francisco Barbas del Buey
MGMarcos Alonso García
Marcos Alonso García
NLNoelia Cenamor Largo
Noelia Cenamor Largo
AJAlba Nieto Juliá
Alba Nieto Juliá
VRVaccination Centre Of Madrid Region
Vaccination Centre Of Madrid Region
Background: Appropriate vaccination strategies have been key to controlling the outbreak of mpox outside endemic areas in 2022, yet few studies have provided information on mpox vaccine effectiveness (VE). Aim: To assess VE after one dose of a third-generation smallpox vaccine against mpox when given as post-exposure prophylaxis (PEP) within 14 days. Methods: A survival analysis in a prospective cohort of close contacts of laboratory-confirmed mpox cases was conducted from the beginning of the outbreak in the region of Madrid in May 2022. The study included contacts of cases in this region diagnosed between 17 May and 15 August 2022. Follow up was up to 49 days. A multivariate proportional hazard model was used to evaluate VE in the presence of confounding and interaction. Results: Information was obtained from 484 close contacts, of which 230 were vaccinated within 14 days of exposure. Of the close contacts, 57 became ill during follow-up, eight vaccinated and 49 unvaccinated. The adjusted effectiveness of the vaccine was 88.8% (95% CI: 76.0–94.7). Among sexual contacts, VE was 93.6% (95% CI: 72.1–98.5) for non-cohabitants and 88.6% (95% CI: 66.1–96.2) for cohabitants. Conclusion: Post-exposure prophylaxis of close contacts of mpox cases is an effective measure that can contribute to reducing the number of cases and eventually the symptoms of breakthrough infections. The continued use of PEP together with pre-exposure prophylaxis by vaccination and other population-targeted prevention measures are key factors in controlling an mpox outbreak.

6 July 2023 in Eurosurveillance
Verified
Journal Article
Open access
SMSarah E McFarland
Sarah E McFarland
UMUlrich Marcus
Ulrich Marcus
LHLukas Hemmers
Lukas Hemmers
FMFuminari Miura
Fuminari Miura
JMJesús Iñigo Martínez
Jesús Iñigo Martínez
ABAlexander Bartel
Alexander Bartel
Background: Since May 2022, an mpox outbreak affecting primarily men who have sex with men (MSM) has occurred in numerous non-endemic countries worldwide. As MSM frequently reported multiple sexual encounters in this outbreak, reliably determining the time of infection is difficult; consequently, estimation of the incubation period is challenging. Aim: We aimed to provide valid and precise estimates of the incubation period distribution of mpox by using cases associated with early outbreak settings where infection likely occurred. Methods: Colleagues in European countries were invited to provide information on exposure intervals and date of symptom onset for mpox cases who attended a fetish festival in Antwerp, Belgium, a gay pride festival in Gran Canaria, Spain or a particular club in Berlin, Germany, where early mpox outbreaks occurred. Cases of these outbreaks were pooled; doubly censored models using the log-normal, Weibull and Gamma distributions were fitted to estimate the incubation period distribution. Results: We included data on 122 laboratory-confirmed cases from 10 European countries. Depending on the distribution used, the median incubation period ranged between 8 and 9 days, with 5th and 95th percentiles ranging from 2 to 3 and from 20 to 23 days, respectively. The shortest interval that included 50% of incubation periods spanned 8 days (4–11 days). Conclusion: Current public health management of close contacts should consider that in approximately 5% of cases, the incubation period exceeds the commonly used monitoring period of 21 days.

8 June 2024 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
JBJosé Francisco Barbas del Buey
José Francisco Barbas del Buey
JMJesús Íñigo Martínez
Jesús Íñigo Martínez
MGMarcos Alonso García
Marcos Alonso García
APAndrés Aragón Peña
Andrés Aragón Peña
LMLaura Montero Morales
Laura Montero Morales
AAAraceli Arce Arnáez
Araceli Arce Arnáez
Introduction: An appropriate vaccination approach is critical to control the current outbreak of mpox but there is little research providing information on its effectiveness, particularly under circumstances of limited vaccine availability. Methods: Pre-exposure vaccination campaign in the Madrid region, with the modified vaccinia Ankara-Bavarian Nordic was indicated in the risk groups from 18 July 2022. To evaluate the vaccine effectiveness (VE) of a dose of third-generation smallpox vaccine against mpox in the context of pre-exposure prophylaxis, a population-based indirect cohort study (Broome method) also known as test-negative design (TND) was conducted in the Madrid region (6 751 251 inhabitants). Logistic regression was used to obtain the adjusted VE in the TND with its time–response relationship and for the sensitivity analysis the conditional logistic regression for matched case–control groups. Results: By epidemiological surveillance, 1690 suspected episodes of mpox were detected of which 799 were cases and 891 controls. The overall adjusted effectiveness of the pre-exposure vaccination against mpox considering an induction period of 14 days, was 86.4% (95% CI 62.2% to 95.1%). VE increases, with a statistically significant time–response effect, being greater than 77.4% with a 95% confidence level from week 7. The VE at eighth week of vaccination was 99% (95% CI 81.7% to 99.9%). Conclusions: The effectiveness of single-dose pre-exposure vaccination against mpox seems very high. Therefore, it appears as a reliable measure to minimise the spread of mpox. The progressive increase in the effectiveness could justify the delay in the administration of the second dose in situations of shortage of vaccines or prioritisation in the vaccination of the maximum number of subjects at risk. Further studies evaluating the long-term effectiveness of the full vaccination would be appropriate.

24 August 2023 in Eurosurveillance
Verified
Journal Article
Open access
LMLaura Montero Morales
Laura Montero Morales
JBJosé Francisco Barbas del Buey
José Francisco Barbas del Buey
MGMarcos Alonso García
Marcos Alonso García
JMJesús Iñigo Martínez
Jesús Iñigo Martínez
NLNoelia Cenamor Largo
Noelia Cenamor Largo
AAAraceli Arce Arnáez
Araceli Arce Arnáez
Eurosurveillance.org is the online home of Eurosurveillance, Europe's journal on infectious disease surveillance, epidemiology, prevention and control.

13 August 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JSJuan Carlos Sanz
Juan Carlos Sanz
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa
JÍJesús Íñigo-Martínez
Jesús Íñigo-Martínez
FMFernando Martín-Martínez
Fernando Martín-Martínez
AHAna María Humanes-Navarro
Ana María Humanes-Navarro
MAMaría Araceli Arce-Arnáez
María Araceli Arce-Arnáez

3 February 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JÍJesús Íñigo-Martínez
Jesús Íñigo-Martínez
JSJuan Carlos Sanz
Juan Carlos Sanz
FMFernando Martín-Martínez
Fernando Martín-Martínez
MGMacarena Garrido-Estepa
Macarena Garrido-Estepa
AHAna María Humanes-Navarro
Ana María Humanes-Navarro
MAMaría Araceli Arce-Arnáez
María Araceli Arce-Arnáez